Verve Therapeutics (NASDAQ:VERV) Earns Buy Rating from HC Wainwright
Verve Therapeutics (NASDAQ:VERV – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $15.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 177.78% from the company’s previous close. Several other research […]
Verve Therapeutics (NASDAQ:VERV – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $15.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 177.78% from the company’s previous close. Several other research […]
